MARTEK BIOSCIENCES CORP
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY10 | FY09 | FY08 | |
|---|---|---|---|
| Revenue | $450.0M | $345.2M | $352.4M |
| Operating income | $50.8M | $63.6M | $56.2M |
| Net income | $27.9M | $40.6M | $37.7M |
| Total assets | $798.8M | $689.8M | — |
| Total liabilities | $127.8M | $53.7M | — |
| Equity | $671.0M | $636.1M | $588.6M |
| EPS (diluted) | $0.83 | $1.22 | $1.13 |
| Shares out. | 33.5M | 33.3M | 33.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2010- Operating margin
- 11.3%
- Net margin
- 6.2%
- Return on equity
- 4.2%
- Return on assets
- 3.5%
- Return on capital (ROCE)
- 6.8%
- Liabilities / assets
- 16.0%
- Debt / equity
- 0.19×
- Book value / share
- $20.02
- Revenue growth (YoY)
- 30.4%
- Net income growth (YoY)
- −31.3%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2010- Altman Z″ (distress)
- 7.92safe
- Accruals / assets
- −14.8%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 6 good- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Delisting / listing-standard notice · Unregistered equity sale · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsFeb 25, 2011
- Entered a material agreement · Regulation FD disclosureDec 21, 2010
- Entered a material agreementDec 17, 2010
- Results of operationsDec 8, 2010
- Entered a material agreementDec 2, 2010
- Regulation FD disclosureNov 24, 2010
- Costs from exit or disposal · Material impairmentSep 28, 2010
- Results of operationsSep 1, 2010
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.